Top 10 MDMA Papers for PTSD

This trial tests MDMA-assisted therapy for PTSD under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA-assisted therapy for PTSD performs when tested under more structured clinical conditions. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.

In the first randomised controlled pilot trial, MDMA-assisted psychotherapy produced greater reductions in Clinician-Administered PTSD Scale scores than placebo in participants with chronic, treatment‑resistant post‑traumatic stress disorder. There were no drug‑related serious adverse events, adverse neurocognitive effects or clinically significant blood pressure increases, suggesting MDMA may be a safe and effective adjunct to psychotherapy in refractory PTSD. For readers, the value is not just the result but the study design: it shows how MDMA-assisted therapy for PTSD performs when tested under more structured clinical conditions.

This trial tests MDMA-assisted therapy for PTSD under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA-assisted therapy for PTSD performs when tested under more structured clinical conditions. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.

This trial tests MDMA-assisted therapy for PTSD under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA-assisted therapy for PTSD performs when tested under more structured clinical conditions. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.

This trial tests MDMA-assisted therapy for PTSD under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA-assisted therapy for PTSD performs when tested under more structured clinical conditions. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.

This paper helped define the clinical evidence for MDMA-assisted therapy for PTSD, including what benefits appear durable and what still needs careful testing. It also shows why therapy structure, follow-up, and participant selection matter as much as the acute drug session. It adds a concrete angle on MDMA-assisted therapy for PTSD, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.

This trial tests MDMA-assisted therapy for PTSD under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA-assisted therapy for PTSD performs when tested under more structured clinical conditions. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.

In this randomised phase 2 dose‑response trial, two active MDMA doses given with eight‑hour psychotherapy sessions produced larger reductions in clinician‑rated PTSD severity than a low dose. Benefits were sustained at 12‑month follow‑up and the treatment was well tolerated with no drug‑related serious adverse events. For readers, the value is not just the result but the study design: it shows how MDMA-assisted therapy for PTSD performs when tested under more structured clinical conditions. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.

The review (2018) suggests how memory reconsolidation and fear extinction may play a significant role in the potent therapeutic effects of MDMA in the treatment of PTSD. It adds a concrete angle on MDMA-assisted therapy for PTSD, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.

The small double-blind placebo-controlled study studied the safety (psychological & physiological) of a low dose of MDMA in women with chronic PTSD and found no adverse effects. It adds a concrete angle on MDMA-assisted therapy for PTSD, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating MDMA-assisted therapy for PTSD as a single settled topic.